Volver al buscador
FDAFDA · Alimentos y medicamentos·N.º oficial Z-0672-2013

Bausch and Lomb 27G sterile cannula packed in the Bausch and Lomb Amvisc 1.2% Sodium Hyaluronate ( Model 59051, 59081, 59051L, 59081L) and Amvisc Plus 1.6% Sodium Hyaluronate (Model 60081, 60051, 60051L, 60081L) ophthalmic viscosurgical device. The 27G disposable cannula is attached to the syringe standard luer fitting to deliver the Amvis or Amvis Plus during use as a surgical aid in opthalmic anterior or posterior segment procedures.

Publicado el 23 de enero de 2013 · Inicio del retiro: 15 de noviembre de 2012

Resumen

FDA registra el retiro Z-0672-2013 de dispositivos médicos de Clase I, publicado el 23 de enero de 2013 e iniciado el 15 de noviembre de 2012. Empresa responsable: Bausch and Lomb, Incorporated; Estado: Finalizado; Cantidad reportada: 2,515,760; Lote: Lot Numbers: 23632, 23633, 23639, 23640, 23647, 23801, 23811, 23863, 23886, 23897, 23920, 23933, 23972, 24022, 24025, 24028, 24257, 24323, 24436, B100003C, B100003E, B100003G, B100015A, B100015D, B100023A, B100023B, B100023C, B100023D, B100023E, B100039C, B100039D, B100039F, B100046A, B100046B, B100046C, B100058A, B100069A, B100069E, B110027D, B110028C, B110048A, B110048D, B110056A, B120011D, B120016A, B120046C, C100039A, C100039B, C10003B, C100046A, C100046B, C100046C, D090095B, D090096A, D090096C, D090097C, D090097D, D090097E, D090097G, D090105B, D090105C, D090105D, D100007B, D100007C, D100008A, D100008B, D100009A, D100011A, D100011B, D100011C, D100016A, D100016B, D100016C, D100016D, D100022A, D100022B, D100022C, D100022D, D100026A, D100026B, D100026C, D100026D, D100026E, D100030A, D100030B, D100030C, D100035A, D100035B, D100035C, D100035D, D100043A, D100043B, D100043C, D100044A, D100044B, D100044C, D100044D, D100044E, D100045A, D100045B, D100045C, D100045D, D100059A, D100059B, D100059C, D100060A, D100060B, D100061A, D100061B, D100080A, D100081A, D100081AR, D100081AS, D110015A, D110015B, D110016A, D110045A, D110046A, D110047A, D110070A, D110071A, D110072A, D110090A, D110090B, D110091A, D110092A, D110108A, D110108B, D110108BR, D120015A, D120015B, D120027A, D120028A, D120029A, D120029B, D120038B, D120039A, D120056B, D120068A, D120068B, E090105A, E100016A, E100016B, E100035A, E100035B, E100035C, E100045A, E100045B, E100059A, E100059B, E100060A, E100060B, E100060C, E100061A, Amvisc 1.2% Sodium Hyaluronate ( Model 59051, 59081, 59051L, 59081L) Amvisc Plus 1.6% Sodium Hyaluronate (Model 60081, 60051, 60051L, 60081L). La Clase I indica una probabilidad razonable de consecuencias graves para la salud o muerte.

Estado reportado al momento de publicación: Terminated — openFDA actualiza semanalmente y este campo no refleja el estado más reciente. Confirma siempre con la fuente oficial.

Qué peligro representa

Some disposable cannulas (with 4-digit lot numbers) provided with the Amvisc or Amvisc Plus OVD are not properly engaging to the Luer-Lock on the Amvisc and Amvisc Plus sterile glass syringes. The cannulas may leak viscoelastic material or detach from the syringe during injection. In rare incidents, detachment has resulted in serious patient injury.

Qué hacer

Voluntary: Firm initiated · E-Mail

Recibe un correo cuando FDA publique un retiro como este

Gratis. Solo te escribimos cuando hay un retiro nuevo que coincide. Te das de baja con un clic.

Detalles del retiro

Fabricante
Bausch and Lomb, Incorporated
Distribuidor
Worldwide distribution: USA including DC and PR; and countries of: Canada and Mexico accounts not available at this time.
Lote
Lot Numbers: 23632, 23633, 23639, 23640, 23647, 23801, 23811, 23863, 23886, 23897, 23920, 23933, 23972, 24022, 24025, 24028, 24257, 24323, 24436, B100003C, B100003E, B100003G, B100015A, B100015D, B100023A, B100023B, B100023C, B100023D, B100023E, B100039C, B100039D, B100039F, B100046A, B100046B, B100046C, B100058A, B100069A, B100069E, B110027D, B110028C, B110048A, B110048D, B110056A, B120011D, B120016A, B120046C, C100039A, C100039B, C10003B, C100046A, C100046B, C100046C, D090095B, D090096A, D090096C, D090097C, D090097D, D090097E, D090097G, D090105B, D090105C, D090105D, D100007B, D100007C, D100008A, D100008B, D100009A, D100011A, D100011B, D100011C, D100016A, D100016B, D100016C, D100016D, D100022A, D100022B, D100022C, D100022D, D100026A, D100026B, D100026C, D100026D, D100026E, D100030A, D100030B, D100030C, D100035A, D100035B, D100035C, D100035D, D100043A, D100043B, D100043C, D100044A, D100044B, D100044C, D100044D, D100044E, D100045A, D100045B, D100045C, D100045D, D100059A, D100059B, D100059C, D100060A, D100060B, D100061A, D100061B, D100080A, D100081A, D100081AR, D100081AS, D110015A, D110015B, D110016A, D110045A, D110046A, D110047A, D110070A, D110071A, D110072A, D110090A, D110090B, D110091A, D110092A, D110108A, D110108B, D110108BR, D120015A, D120015B, D120027A, D120028A, D120029A, D120029B, D120038B, D120039A, D120056B, D120068A, D120068B, E090105A, E100016A, E100016B, E100035A, E100035B, E100035C, E100045A, E100045B, E100059A, E100059B, E100060A, E100060B, E100060C, E100061A, Amvisc 1.2% Sodium Hyaluronate ( Model 59051, 59081, 59051L, 59081L) Amvisc Plus 1.6% Sodium Hyaluronate (Model 60081, 60051, 60051L, 60081L)
Clasificación de riesgo
Class I
Área (FDA)
device
País
United States

Retiros relacionados

Preguntas sobre este retiro

¿Bausch and Lomb 27G sterile cannula packed in the Bausch and Lomb Amvisc 1.2% Sodium Hyaluronate ( Model 59051, 59081, 59051L, 59081L) and Amvisc Plus 1.6% Sodium Hyaluronate (Model 60081, 60051, 60051L, 60081L) ophthalmic viscosurgical device. The 27G disposable cannula is attached to the syringe standard luer fitting to deliver the Amvis or Amvis Plus during use as a surgical aid in opthalmic anterior or posterior segment procedures. fue retirado del mercado?

Sí. FDA publicó el retiro Z-0672-2013 el 23 de enero de 2013. Peligro reportado: Some disposable cannulas (with 4-digit lot numbers) provided with the Amvisc or Amvisc Plus OVD are not properly engaging to the Luer-Lock on the Amvisc and Amvisc Plus sterile glass syringes. The cannulas may leak viscoelastic material or detach from the syringe during injection. In rare incidents, detachment has resulted in serious patient injury.

¿Qué debo hacer si tengo este producto?

Voluntary: Firm initiated · E-Mail